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Significant progress has been made in the treatment of CML with allogeneic bone marrow transplantation (BMT). Several studies have reported long-term survival of 50-80% and disease-free survival rates of 30-70% after BMT in CP. 1 Results are better for patients allografted in CP than AP or BP. Although disease phase has been recognised as the principal prognostic factor, patient age, duration of disease and pre-transplant chemotherapy have all been identified as significant contributors to the prediction of outcome post BMT.
Few studies have examined the prognostic significance of chromosomal findings in patients undergoing BMT for CML. Przepiorka and Thomas 2 reported that VPh, +8 and +Ph are associated with high risk of relapse after BMT for CML in advanced disease as were those with VPh, while iso(17q) alone was not. Slovak et al 3 examined the diseasefree survival of 31 patients transplanted in AP and BP and concluded that the presence of +8, iso(17q) and +Ph did not confer a worse prognosis.
The aim of this study was to evaluate the influence of pre-transplant cytogenetic status on outcome after BMT from sibling or volunteer unrelated donors for CML in pre-BP.
Methods

Patients
We retrospectively reviewed the pre-transplant cytogenetic data of 418 patients with pre-BP CML who underwent BMT from identical sibling (n = 264) or volunteer unrelated donors (n = 154) between February 1981 and January 1998. Of these patients 333 were in 1st CP, 23 in 2nd CP and 62 in AP. The patients were divided into five groups according to their pre-transplant cytogenetic status: A = 344 (82.3%) with the Ph translocation alone; B = 13 (3.1%) Ph−, BCR-ABL+ (two Ph− patients who were also BCR-ABL negative were excluded); C = 17 (4.0%) with VPh; D = 19 (4.5%) with Ph chromosome plus at least one of: trisomy 8, +Ph, chromosome 17 abnormalities (iso(17q) or abnormalities of 17p), and E = 25 (6.0%) with any other CP = chronic phase; AP = accelerated phase; GVHD = graft-versus-host disease; TCD = T cell depletion; VUD = volunteer unrelated donor; CMV = cytomegalovirus; Bu = busulphan; Cy = cyclophosphamide; TBI = total body irradiation.
abnormality in addition to the Ph chromosome; the most frequent abnormalities were those of chromosome 7 (−7; i(7)(q10),i(7)(p10); inv (7)(q11.2q22.1); del(7)(p1?3p1?5)) and chromosome 19 (add(19)(p1); add(19)(p1)).
Patients were classified into AP or CP according to Hammersmith criteria described by Savage et al. 4 All patients received conditioning which consisted of cyclophosphamide Ϯ busulphan, total body irradiation, splenic irradiation, daunorubicin and additional immunosuppression. Graft-versus-host disease (GVHD) prophylaxis was provided by in vivo or ex vivo T cell depletion for 219 patients.
The patients' characteristics are shown in Table 1 .
Cytogenetics
Cytogenetic analysis was routinely performed 1 month before BMT using standard techniques. 5 Three cultures were prepared from each sample: a direct culture (colcemid added for 1 h or overnight before harvesting) and two shortterm cultures (24-72 h), one of which was synchronised to produce extended chromosomes. 6 At least 10 G-banded metaphases were analysed per patient. An abnormality was identified as clonal when it was present in at least two (structural abnormality or extra chromosome) or three (loss of a chromosome) metaphases. Chromosomal abnormalities were described according to standard nomenclature. 7 
Statistical analysis
Survival and leukaemia-free probabilities were calculated by the method of Kaplan and Meier. 8 The probability of relapse was calculated by the cumulative incidence procedure where relapse was the failure of interest, and death without relapse was the competing risk. 9 To test the association between cytogenetic status and treatment failure a proportional hazards regression analysis was carried out with adjustment for donor match, disease status, duration of disease, patient CMV status and GVHD prophylaxis. All quoted P values are two sided, and confidence intervals refer to 95% boundaries. 
Results
We estimated the probabilities of survival, leukaemia-free survival (LFS) (defined as survival without recurrence of molecular, cytogenetic or haematological relapse) and of relapse at 5 years for all groups. Wide confidence intervals were observed for groups B-E and the results should be treated with caution. In addition, for groups B-E we calculated the relative risks of treatment failure (defined as relapse or death) when adjusted for donor match, disease status, duration of disease, patient CMV status and GVHD prophylaxis in comparison with group A. The results are shown in Tables 2 and 3 .
Survival at 5 years
Patients with the Ph translocation alone showed a survival rate of 51.8%, which was similar to that of patients with a VPh (58.8%). Ph− patients had a higher survival rate (76.9%) while all patients with additional abnormalities showed a lower survival (D = 44.7%; E = 40.4%).
LFS at 5 years
Patients with the Ph translocation alone showed a LFS of 31.9% which was similar to that of patients with +8, +Ph and i(17q) (40.6%). Ph− patients had high LFS (76.9%), while those with VPh or the other additional abnormalities had a lower LFS (22.1% and 16%).
Relapse at 5 years
None of the Ph− patients relapsed; there was no difference in the 5 year relapse probabilities of all other groups (range 33-44%).
Relative risk of treatment failure
Compared to patients with the Ph translocation alone, those with +8, +Ph and i(17q) had a significantly lower risk (0.43, P = 0.02); Ph− patients also showed a lower risk although this was not statistically significant (0.49, P = 0.12). Those with a variant translocation showed a statistically significant higher risk (1.92, P = 0.03) than patients with the Ph translocation alone.
Discussion
We draw two principal conclusions from this study. Firstly, patients with the standard Ph translocation, VPh translocations and Ph− CML may have different outcomes: Ph− patients showed a better outcome, and VPh a worse outcome than patients with a standard t(9;22). Secondly, those with the additional changes of +8, +Ph and i(17q) do not necessarily show a worse outcome than those with no additional changes, whereas those with other additional changes may fare worst of all. Both of these findings are surprising. Generally, the three cytogenetic manifestations of the BCR-ABL rearrangement, the standard t(9;22), VPh translocation and a normal karyotype (Ph−), are not thought to confer different prognoses. Although one report found a distinctly reduced survival in patients with a VPh, 10 several other reports have failed to confirm this finding. 11 At present, explanations for any differences between standard Ph, VPh and Ph− CML are speculative. One possibility is that the position of the third breakpoint of the VPh may have an adverse effect. However, since the localisations of the third breakpoint are widely distributed, with only slight chromosomal clustering, 12 it is unlikely that genetic lesions of clinical consequence would occur sufficiently frequently at the third breakpoint. A second factor may be the presence of deletions at the site of the Ph translocation. 13 Preliminary evidence indicates that these occur more frequently in VPh Bone Marrow Transplantation than t(9;22) patients 14 although this has yet to be fully explored and their frequency in Ph− patients has not been examined.
The significance of cytogenetic abnormalities in addition to the Ph translocation is also uncertain. Although clonal cytogenetic evolution at any stage of the disease has been associated with shorter survival, the presence of additional chromosome changes, particularly +8 and +Ph, can be compatible with CP disease. In one study of patients transplanted in AP, the 4-year probability of survival for patients categorised as AP on the basis of factors other than cytogenetic abnormalities was 0.34 compared with 0.66 for those categorised as in AP solely on the basis of additional cytogenetic changes. 15 Two other studies have examined the effect of pre-BMT cytogenetics upon BMT outcome. Przepiorka and Thomas 2 examined 126 patients with AP or BP CML, in whom additional cytogenetic abnormalities were found in 84% and a VPh in 14%. Patients with a VPh, and those with a +8 or +Ph, showed a higher risk of relapse. Although in our study VPh was not associated with a higher relapse, it was associated with a reduced LFS and higher relative risk of treatment failure. One important difference is that Przepiorka and Thomas examined AP and BP patients while we examined patients with less advanced disease. In a second study, Slovak et al 3 examined 21 CML patients in AP, 10 of whom showed additional cytogenetic abnormalities. No difference was found between those with and without additional abnormalities, which is similar to our finding in group D (+8, +Ph, i(17q)) but not in group E (other changes). Unfortunately, neither group examined Ph− CML patients, who showed a particularly good outcome in our series.
In conclusion, we have shown that pre-BMT cytogenetic status may provide important information on BMT outcome for patients transplanted in CP or AP. However, the differences between t(9;22), VPh and Ph− CML and those with additional cytogenetic abnormalities that we have identified in our series are surprising and thus require confirmation by other studies.
